LIVN - LivaNova PLC Stock Price, Fair Value and News

53.49USD+1.16 (+2.22%)Delayed as of 22 Apr 2024, 12:03 pm ET

Market Summary

USD53.49+1.16

Delayedas of 22 Apr 2024, 12:03 pm

2.22%

LIVN Stock Price

View Fullscreen

LIVN RSI Chart

LIVN Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

160.92

Price/Sales (Trailing)

2.45

EV/EBITDA

1.3K

Price/Free Cashflow

70.71

LIVN Price/Sales (Trailing)

LIVN Profitability

EBT Margin

-7.04%

Return on Equity

1.37%

Return on Assets

0.72%

Free Cashflow Yield

1.41%

LIVN Fundamentals

LIVN Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

12.83%

Rev. Growth (Qtr)

8.39%

LIVN Earnings

Earnings (TTM)

17.5M

Earnings Growth (Yr)

883.68%

Earnings Growth (Qtr)

323.27%

Breaking Down LIVN Revenue

52 Week Range

43.6359.86

(Low)(High)

Last 7 days

-1.3%

Last 30 days

-7.7%

Last 90 days

4.1%

Trailing 12 Months

5.4%

How does LIVN drawdown profile look like?

LIVN Financial Health

Current Ratio

2.95

Debt/Equity

0.44

Debt/Cashflow

0.13

LIVN Investor Care

Shares Dilution (1Y)

0.73%

Diluted EPS (TTM)

0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.0B	1.1B	1.1B	1.2B
2022	1.0B	1.0B	1.0B	1.0B
2021	939.4M	1.0B	1.0B	1.0B
2020	1.1B	980.8M	952.3M	934.2M
2019	1.1B	1.1B	1.1B	1.1B
2018	1.0B	1.1B	1.1B	1.1B
2017	782.5M	799.8M	983.6M	1.0B
2016	640.9M	811.4M	982.4M	782.7M
2015	253.7M	255.8M	263.4M	294.7M
2014	275.1M	282.0M	285.1M	288.5M
2013	0	254.3M	261.2M	268.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of LivaNova PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 30, 2024	shvartsburg alex	sold (taxes)	-352,981	55.94	-6,310	cfo
Mar 30, 2024	bolton stephanie	sold (taxes)	-203,789	55.94	-3,643	president, global epilepsy
Mar 30, 2024	hutchinson michael damon	acquired	-	-	1,478	chief legal officer
Mar 30, 2024	shvartsburg alex	acquired	-	-	14,752	cfo
Mar 30, 2024	hutchinson michael damon	sold (taxes)	-30,319	55.94	-542	chief legal officer
Mar 30, 2024	hebbelinck trui	sold (taxes)	-309,964	55.94	-5,541	chief human resources officer
Mar 30, 2024	hebbelinck trui	acquired	-	-	11,779	chief human resources officer
Mar 30, 2024	bolton stephanie	acquired	-	-	7,744	president, global epilepsy
Feb 29, 2024	kozy william a	acquired	-	-	14,512	chairman and ceo
Feb 29, 2024	kozy william a	sold (taxes)	-266,980	54.81	-4,871	chairman and ceo

Which funds bought or sold LIVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	SJS Investment Consulting Inc.	added	11.11	94.00	560	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-4.92	1,201,030	44,123,300	0.07%
Apr 18, 2024	STATE OF MICHIGAN RETIREMENT SYSTEM	added	2.32	71,008	739,023	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	101	1,343	-%
Apr 18, 2024	Diversified Trust Co	added	6.58	95,323	721,066	0.02%
Apr 18, 2024	Hexagon Capital Partners LLC	added	110	9,855	17,565	-%
Apr 17, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	reduced	-7.34	262,000	826,000	0.03%
Apr 16, 2024	Financial Management Professionals, Inc.	unchanged	-	-	-	-%
Apr 16, 2024	Perpetual Ltd	added	3.02	1,255,020	12,280,400	0.12%
Apr 15, 2024	NorthCrest Asset Manangement, LLC	reduced	-1.34	18,092	289,210	0.01%

Are Funds Buying or Selling LIVN?

Are funds buying LIVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIVN

No. of Funds

Unveiling LivaNova PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	integrated core strategies (us) llc	5.1%	2,733,440	SC 13G
Feb 12, 2024	primecap management co/ca/	10.75%	5,791,280	SC 13G/A
Jan 23, 2024	blackrock inc.	13.8%	7,415,557	SC 13G/A
May 09, 2023	primecap management co/ca/	10.07%	5,394,100	SC 13G/A
Feb 14, 2023	harris associates l p	3.8%	2,008,159	SC 13G/A
Feb 09, 2023	primecap management co/ca/	8.58%	4,594,917	SC 13G/A
Jan 26, 2023	blackrock inc.	12.8%	6,834,335	SC 13G/A
Jan 20, 2023	blackrock inc.	12.8%	6,834,335	SC 13G/A
Feb 11, 2022	harris associates l p	7.2%	3,823,266	SC 13G/A
Feb 10, 2022	primecap management co/ca/	8.3%	4,415,445	SC 13G/A

Recent SEC filings of LivaNova PLC

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 11, 2024	3	Insider Trading
Mar 08, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to LivaNova PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

LivaNova PLC News

Latest updates

LivaNova PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	8.4%	310	286	294	263	275	253	254	240	270	253	264	248	270	240	182	242	288	269	277	251	297
Gross Profit	-5.8%	190	202	205	174	184	171	184	168	202	169	172	163	167	148	115	165	193	-	-	-	-
S&GA Expenses	-1.1%	133	135	126	124	120	115	116	119	124	109	123	116	117	104	103	120	153	123	127	126	122
R&D Expenses	-0.8%	46.00	47.00	51.00	50.00	45.00	36.00	34.00	41.00	44.00	42.00	53.00	45.00	44.00	47.00	25.00	36.00	23.00	46.00	35.00	44.00	38.00
EBITDA Margin	-97.7%	0.00*	0.09*	-0.01*	0.01*	0.00*	-0.02*	0.04*	-0.02*	-0.05*	-0.33*	-0.30*	-0.31*	-	-	-	-	-	-	-	-	-
Interest Expenses	4.2%	16.00	15.00	15.00	13.00	13.00	13.00	14.00	8.00	6.00	11.00	17.00	16.00	16.00	15.00	6.00	5.00	5.00	5.00	4.00	2.00	2.00
Income Taxes	-2184.6%	-110	5.00	4.00	2.00	5.00	1.00	3.00	3.00	3.00	2.00	4.00	3.00	-18.54	-3.99	66.00	-44.71	-6.94	-10.65	-6.16	-6.61	-69.83
Earnings Before Taxes	-4667.2%	-94.30	-1.98	5.00	10.00	6.00	-106	19.00	6.00	-2.30	-41.56	-52.54	-28.08	-301	-18.71	-21.66	-6.01	-152	21.00	-35.56	-21.46	-279
EBT Margin	-504.6%	-0.07*	0.02*	-0.08*	-0.07*	-0.07*	-0.08*	-0.02*	-0.09*	-0.12*	-0.41*	-0.39*	-0.39*	-	-	-	-	-	-	-	-	-
Net Income	323.3%	16.00	-7.32	1.00	7.00	2.00	-107	16.00	3.00	-5.13	-43.44	-56.49	-30.76	-281	-14.81	-89.41	36.00	-143	32.00	-29.21	-14.85	-210
Net Income Margin	493.0%	0.02*	0.00*	-0.09*	-0.08*	-0.08*	-0.09*	-0.03*	-0.10*	-0.13*	-0.40*	-0.37*	-0.44*	-	-	-	-	-	-	-	-	-
Free Cashflow	335.8%	41.00	9.00	-23.60	13.00	10.00	30.00	-16.37	21.00	26.00	21.00	19.00	11.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	4.3%	2,430	2,329	2,342	2,295	2,295	2,213	2,336	2,417	2,201	2,203	2,397	2,369	2,400	2,522	2,503	2,454	2,412	2,510	2,622	2,600	2,550
Current Assets	3.6%	988	954	942	903	886	851	772	810	679	646	809	691	708	673	672	617	549	547	568	541	533
Cash Equivalents	13.9%	267	234	223	214	214	506	407	442	208	182	329	253	253	228	233	126	61.00	75.00	45.00	51.00	47.00
Inventory	-8.5%	148	162	156	142	129	122	119	115	106	124	127	125	115	178	177	170	164	168	169	161	154
Net PPE	3.3%	154	149	150	149	147	139	143	148	150	153	157	158	164	191	186	184	181	180	185	186	191
Goodwill	2.1%	783	767	779	774	769	742	898	897	900	905	918	910	922	918	902	889	916	946	962	952	957
Liabilities	4.3%	1,152	1,104	1,101	1,068	1,087	1,066	1,054	1,125	906	891	1,356	1,303	1,291	1,171	1,169	1,062	1,028	1,015	1,138	1,113	1,046
Current Liabilities	13.4%	335	295	288	316	297	288	264	308	697	658	702	295	309	282	268	530	513	469	596	622	497
Long Term Debt	0.1%	569	568	568	520	518	518	460	456	10.00	11.00	431	646	642	637	639	316	260	273	174	142	140
LT Debt, Non Current	0.1%	569	568	568	520	518	518	460	456	10.00	11.00	431	646	642	637	639	316	260	273	174	142	140
Shareholder's Equity	4.3%	1,278	1,225	1,241	1,227	1,208	1,147	1,282	1,292	1,295	1,299	1,029	1,055	1,109	1,351	1,333	1,393	1,378	1,495	1,483	1,487	1,500
Retained Earnings	1.7%	-966	-982	-975	-976	-984	-985	-878	-894	-897	-879	-837	-782	-761	-472	-457	-369	-406	-263	-295	-266	-251
Additional Paid-In Capital	0.4%	2,190	2,181	2,169	2,163	2,158	2,144	2,133	2,121	2,118	2,107	1,779	1,770	1,768	1,758	1,751	1,740	1,735	1,725	1,717	1,707	1,705
Shares Outstanding	0.1%	54.00	54.00	54.00	54.00	54.00	53.00	53.00	53.00	51.00	52.00	49.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,800	-	-	-	3,300	-	-	-	4,100	-	-	-	2,300	-	-	-	3,500	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	197.5%	53,958	18,136	-17,937	20,757	18,703	35,638	-10,243	25,823	33,480	23,953	25,631	19,480	36,985	8,657	-19,019	-106,045	2,866	-76,587	-19,395	1,974	20,890
Share Based Compensation	-29.7%	8,283	11,779	5,711	10,579	12,317	10,727	11,509	10,256	9,990	11,122	9,916	9,536	8,244	7,811	9,991	9,043	8,426	8,531	8,724	6,872	5,536
Cashflow From Investing	-20.7%	-12,138	-10,054	-6,655	-11,484	-10,953	-5,831	-16,148	-5,482	-3,631	-6,180	56,573	-9,858	-8,507	-10,671	-11,581	-11,085	-10,771	-8,065	-16,813	-5,641	-13,148
Cashflow From Financing	-17.3%	-5,018	-4,277	36,014	-5,235	-1,657	73,230	-6,320	214,877	-3,300	-164,096	-5,759	-8,328	-5,171	-3,770	136,604	183,093	-7,160	116,684	29,468	7,589	-39,438
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

LIVN Income Statement

2023-12-31

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 1,153,545	$ 1,021,805	$ 1,035,365
Cost of sales	382,295	314,577	329,371
Gross profit	771,250	707,228	705,994
Operating expenses:
Selling, general and administrative	518,129	469,243	471,904
Research and development	193,817	155,805	183,414
Impairment of goodwill	0	129,396	0
Total impairment of long-lived assets	89,974	0	0
Other operating expenses	37,828	29,536	51,460
Operating loss	(68,498)	(76,752)	(784)
Interest expense	(58,853)	(48,250)	(50,151)
Loss on debt extinguishment	0	0	(60,238)
Foreign exchange and other income/(expense)	46,125	49,860	(13,299)
Loss before tax	(81,226)	(75,142)	(124,472)
Income tax (benefit) expense	(98,876)	11,051	11,198
Losses from equity method investments	(104)	(53)	(148)
Net income (loss)	$ 17,546	$ (86,246)	$ (135,818)
Basic loss per share (in dollars per share)	$ 0.33	$ (1.61)	$ (2.68)
Diluted loss per share (in dollars per share)	$ 0.32	$ (1.61)	$ (2.68)
Shares used in computing basic loss per share (in shares)	53,939	53,472	50,633
Shares used in computing diluted loss per share (in shares)	54,212	53,472	50,633

LIVN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 266,504	$ 214,172
Restricted cash	311,368	301,446
Accounts receivable, net of allowance of $12,019 at December 31, 2023 and $11,862 at December 31, 2022	215,072	183,110
Inventories	147,887	129,379
Prepaid and refundable taxes	20,145	31,708
Prepaid expenses and other current assets	27,182	26,321
Total Current Assets	988,158	886,136
Property, plant and equipment, net	154,181	147,187
Goodwill	782,941	768,787
Intangible assets, net	261,178	368,559
Operating lease assets	50,845	35,830
Investments	22,843	16,266
Deferred tax assets	118,858	1,384
Long-term derivative assets	38,496	54,393
Other assets	12,063	16,231
Total Assets	2,429,563	2,294,773
Current Liabilities:
Current debt obligations	18,111	23,434
Accounts payable	80,845	74,310
Accrued liabilities and other	107,301	81,481
Current litigation provision liability	10,756	29,481
Taxes payable	23,340	16,505
Accrued employee compensation and related benefits	94,630	72,187
Total Current Liabilities	334,983	297,398
Long-term debt obligations	568,543	518,067
Contingent consideration	80,902	85,292
Deferred tax liabilities	11,567	8,516
Long-term operating lease liabilities	45,388	29,548
Long-term employee compensation and related benefits	17,254	16,804
Long-term derivative liabilities	45,569	85,675
Other long-term liabilities	47,729	45,849
Total Liabilities	1,151,935	1,087,149
Commitments and contingencies (Note 13)
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 53,942,151 shares issued and 53,918,222 shares outstanding at December 31, 2023; 53,851,979 shares issued and 53,564,664 shares outstanding at December 31, 2022	82,533	82,424
Additional paid-in capital	2,189,517	2,157,724
Accumulated other comprehensive loss	(27,883)	(48,119)
Accumulated deficit	(966,484)	(984,030)
Treasury stock at cost, 23,929 ordinary shares at December 31, 2023, 287,315 ordinary shares at December 31, 2022	(55)	(375)
Total Stockholders’ Equity	1,277,628	1,207,624
Total Liabilities and Stockholders’ Equity	$ 2,429,563	$ 2,294,773

About LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

CEO	Mr. William A. Kozy
WEBSITE	livanova.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2900

LivaNova PLC Frequently Asked Questions

What is the ticker symbol for LivaNova PLC? What does LIVN stand for in stocks?

LIVN is the stock ticker symbol of LivaNova PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LivaNova PLC (LIVN)?

As of Fri Apr 19 2024, market cap of LivaNova PLC is 2.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers. The fair value of LivaNova PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LivaNova PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LivaNova PLC a good stock to buy?

The fair value guage provides a quick view whether LIVN is over valued or under valued. Whether LivaNova PLC is cheap or expensive depends on the assumptions which impact LivaNova PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIVN.

What is LivaNova PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, LIVN's PE ratio (Price to Earnings) is 160.92 and Price to Sales (PS) ratio is 2.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIVN PE ratio will change depending on the future growth rate expectations of investors.